Keywords: Biomaterials, Biotechnology, Drug Discovery, Disease Treatment
Nerve injuries occur when a nerve is damaged or compressed, leading to a disruption in its function. Peripheral nerve injuries are located at nerves that connect the brain and spinal cord to the rest of the body and include carpal tunnel syndrome, ulnar nerve compression, and sciatica. There are estimated 50,000 peripheral nerve injuries expected to occur in the US each year. The peripheral nerve injury market in the US was valued at $284.3M in 2021 with expected CAGR of 7.3% through 2030. Traditionally, nerve injuries are treated though surgeries, such as surgical reattachment of nerves or placement of a nerve graft to guide nerve growth, and invasive injections. Therefore, there is a need to development therapies for nerve injuries through less invasive techniques. A Clemson University researcher has developed nanoparticle vesicles that can deliver drugs using non-invasive routes of administrations for the treatment of nerve injuries. These nanoparticles are conjugated with a peptide to increase nerve penetration.
Nerve injury treatment, Nanoparticles
The proposed nanoparticles are polymersomes that are labeled with the rabies virus glycoprotein peptide (RVG). The addition of RVG induces the association of the polymersomes with proteins expressed on nerve cells, increasing nerve retention. These polymersomes were shown to have nerve-penetration capabilities when delivered intranerve or intramuscular, a less invasive route.
Proof of Concept
2024-061
Dr. Jessica Larsen
Pushparajah Thavarajah
Business Development Associate
E: pthavar@clemson.edu
P: (864) 656-0797
Contact
Stay up-to-date with the latest trends in the innovation and research industry. Sign up for our newsletter to see how CURF is making a difference and impacting the economy where we live.